Muhammad Umair Mushtaq

16PUBLICATIONS
35CO-AUTHORS
Molecular targetsTransplantation immunologyCancer therapy (excl. chemotherapy and radiation therapy)Medical mycologyRegenerative medicine (incl. stem cells)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Dec 11, 2025
Comparison of Standard of Care with or Without a PD-1/PD-L-1 Inhibitor for the Treatment of Multiple Myeloma: A Systematic Review and Meta-Analysis of Phase II and III Randomized Controlled Trials.

Zain Alsaddi, Osama Younis, Ghena Khasawneh

|Oct 23, 2025
Remission of <i>TP53</i>-Mutant AML After Transplantation With Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Followed by a Donor-Derived Anti-CD33 Chimeric Antigen Receptor T (VCAR33).

Guenther Koehne, Muhammad U Mushtaq, Lori S Muffly

|Sep 26, 2025
CAR-T Access Disparities for Multiple Myeloma in the Midwest: A Social Determinants of Health Perspective.

Michael Weise, Shebli Atrash, Briha Ansari

|Jul 17, 2025
Impact of body mass index on outcomes following allogeneic hematopoietic stem cell transplantation.

Moazzam Shahzad, Aleenah Mohsin, Ibrahim Khamees

|May 09, 2025
Reduced dose fludarabine and cyclophosphamide lymphodepletion before tumor-infiltrating lymphocyte therapy in melanoma.

Muhammad Umair Mushtaq, Haitham Abdelhakim, Luke Selby

|May 05, 2025
Attitudes and perspectives of oncologists about measurable residual disease testing in multiple myeloma: initiative for standardizing guidelines.

Aqeeb Ur Rehman, Fathima Shehnaz Ayoobkhan, Moazzam Shahzad

Pageof 3

Frequent Collaborators

7 joint publications

Moazzam Shahzad

5 joint publications

Al-Ola Abdallah

4 joint publications

Muhammad Kashif Amin

3 joint publications

Joseph P McGuirk